An engineered heparin-binding form of VEGF-E (hbVEGF-E): Biological effects in vitro and mobilization of precursor cells

Matthias Heil, Rita Mitnacht-Krauss, Katja Issbrücker, Joop Van Den Heuvel, Christoph Dehio, Wolfgang Schaper, Matthias Clauss, Herbert A. Weich

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF-A) is the founding member of a family of angiogenic proteins with various binding abilities to three cognate VEGF receptors. Previously, a gene encoding from the genome of parapox orf virus (OV) with about 25% amino acid identity to mammalian VEGF-A was named VEGF-E and shown to bind and specifically activate the vascular endothelial growth factor receptor VEGFR-2 (KDR/flk-1). Here, we have generated a novel heparin-binding form of VEGF-E by introducing the heparin-domain of the human VEGF-Az65 splice variant into the viral VEGF-E protein. Recombinant heparin-binding VEGF-E (hbVEGF-E) is shown to stimulate proliferation and sprout formation of macro- and microvascular endothelial cells to a similar extent as the parental OV-VEGF-E but fails to activate peripheral mononuclear cells. However, hbVEGF-E is more potent in binding competition assays with primary human endothelial cells when compared to the OV-VEGF-E. This can be explained by our finding that binding of hbVEGF-E but not of parental OV-VEGF-E to the VEGFR-2 is strongly increased by the addition of neuropilin-1 (NP-1), a cognate co-receptor for VEGF-A. The engineered hbVEGF-E was compared with the VEGFR-I selective and also heparin-binding form of placenta growth factor (PIGF-2) in vivo. Both heparin-binding homologues induced mobilization of endothelial progenitor cells from the bone marrow and gave rise to similar colony numbers of myeloic cells in a colony-forming assay. These findings suggest that both VEGFR-1 and VEGFR-2 are involved in stem cell mobilization.

Original languageEnglish
Pages (from-to)201-211
Number of pages11
JournalAngiogenesis
Volume6
Issue number3
DOIs
StatePublished - 2003

Fingerprint

Vascular Endothelial Growth Factor A
Heparin
Orf virus
Viruses
Vascular Endothelial Growth Factor Receptor-2
Endothelial cells
Assays
Vascular Endothelial Growth Factor Receptor
Proteins
Gene encoding
In Vitro Techniques
Endothelial Cells
Angiogenic Proteins
Neuropilin-1
Hematopoietic Stem Cell Mobilization
Stem cells
Vascular Endothelial Growth Factor Receptor-1
Macros
Aptitude
Amino acids

Keywords

  • Endothelial mitogens
  • Heparin-binding growth factors
  • KDR/vascular endothelial growth factor
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Pathology and Forensic Medicine
  • Clinical Biochemistry
  • Polymers and Plastics

Cite this

Heil, M., Mitnacht-Krauss, R., Issbrücker, K., Van Den Heuvel, J., Dehio, C., Schaper, W., ... Weich, H. A. (2003). An engineered heparin-binding form of VEGF-E (hbVEGF-E): Biological effects in vitro and mobilization of precursor cells. Angiogenesis, 6(3), 201-211. https://doi.org/10.1023/B:AGEN.0000021391.88601.92

An engineered heparin-binding form of VEGF-E (hbVEGF-E) : Biological effects in vitro and mobilization of precursor cells. / Heil, Matthias; Mitnacht-Krauss, Rita; Issbrücker, Katja; Van Den Heuvel, Joop; Dehio, Christoph; Schaper, Wolfgang; Clauss, Matthias; Weich, Herbert A.

In: Angiogenesis, Vol. 6, No. 3, 2003, p. 201-211.

Research output: Contribution to journalArticle

Heil, M, Mitnacht-Krauss, R, Issbrücker, K, Van Den Heuvel, J, Dehio, C, Schaper, W, Clauss, M & Weich, HA 2003, 'An engineered heparin-binding form of VEGF-E (hbVEGF-E): Biological effects in vitro and mobilization of precursor cells', Angiogenesis, vol. 6, no. 3, pp. 201-211. https://doi.org/10.1023/B:AGEN.0000021391.88601.92
Heil, Matthias ; Mitnacht-Krauss, Rita ; Issbrücker, Katja ; Van Den Heuvel, Joop ; Dehio, Christoph ; Schaper, Wolfgang ; Clauss, Matthias ; Weich, Herbert A. / An engineered heparin-binding form of VEGF-E (hbVEGF-E) : Biological effects in vitro and mobilization of precursor cells. In: Angiogenesis. 2003 ; Vol. 6, No. 3. pp. 201-211.
@article{561053fb034e48148d615131cbaa2be8,
title = "An engineered heparin-binding form of VEGF-E (hbVEGF-E): Biological effects in vitro and mobilization of precursor cells",
abstract = "Vascular endothelial growth factor (VEGF-A) is the founding member of a family of angiogenic proteins with various binding abilities to three cognate VEGF receptors. Previously, a gene encoding from the genome of parapox orf virus (OV) with about 25{\%} amino acid identity to mammalian VEGF-A was named VEGF-E and shown to bind and specifically activate the vascular endothelial growth factor receptor VEGFR-2 (KDR/flk-1). Here, we have generated a novel heparin-binding form of VEGF-E by introducing the heparin-domain of the human VEGF-Az65 splice variant into the viral VEGF-E protein. Recombinant heparin-binding VEGF-E (hbVEGF-E) is shown to stimulate proliferation and sprout formation of macro- and microvascular endothelial cells to a similar extent as the parental OV-VEGF-E but fails to activate peripheral mononuclear cells. However, hbVEGF-E is more potent in binding competition assays with primary human endothelial cells when compared to the OV-VEGF-E. This can be explained by our finding that binding of hbVEGF-E but not of parental OV-VEGF-E to the VEGFR-2 is strongly increased by the addition of neuropilin-1 (NP-1), a cognate co-receptor for VEGF-A. The engineered hbVEGF-E was compared with the VEGFR-I selective and also heparin-binding form of placenta growth factor (PIGF-2) in vivo. Both heparin-binding homologues induced mobilization of endothelial progenitor cells from the bone marrow and gave rise to similar colony numbers of myeloic cells in a colony-forming assay. These findings suggest that both VEGFR-1 and VEGFR-2 are involved in stem cell mobilization.",
keywords = "Endothelial mitogens, Heparin-binding growth factors, KDR/vascular endothelial growth factor, Vascular endothelial growth factor",
author = "Matthias Heil and Rita Mitnacht-Krauss and Katja Issbr{\"u}cker and {Van Den Heuvel}, Joop and Christoph Dehio and Wolfgang Schaper and Matthias Clauss and Weich, {Herbert A.}",
year = "2003",
doi = "10.1023/B:AGEN.0000021391.88601.92",
language = "English",
volume = "6",
pages = "201--211",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - An engineered heparin-binding form of VEGF-E (hbVEGF-E)

T2 - Biological effects in vitro and mobilization of precursor cells

AU - Heil, Matthias

AU - Mitnacht-Krauss, Rita

AU - Issbrücker, Katja

AU - Van Den Heuvel, Joop

AU - Dehio, Christoph

AU - Schaper, Wolfgang

AU - Clauss, Matthias

AU - Weich, Herbert A.

PY - 2003

Y1 - 2003

N2 - Vascular endothelial growth factor (VEGF-A) is the founding member of a family of angiogenic proteins with various binding abilities to three cognate VEGF receptors. Previously, a gene encoding from the genome of parapox orf virus (OV) with about 25% amino acid identity to mammalian VEGF-A was named VEGF-E and shown to bind and specifically activate the vascular endothelial growth factor receptor VEGFR-2 (KDR/flk-1). Here, we have generated a novel heparin-binding form of VEGF-E by introducing the heparin-domain of the human VEGF-Az65 splice variant into the viral VEGF-E protein. Recombinant heparin-binding VEGF-E (hbVEGF-E) is shown to stimulate proliferation and sprout formation of macro- and microvascular endothelial cells to a similar extent as the parental OV-VEGF-E but fails to activate peripheral mononuclear cells. However, hbVEGF-E is more potent in binding competition assays with primary human endothelial cells when compared to the OV-VEGF-E. This can be explained by our finding that binding of hbVEGF-E but not of parental OV-VEGF-E to the VEGFR-2 is strongly increased by the addition of neuropilin-1 (NP-1), a cognate co-receptor for VEGF-A. The engineered hbVEGF-E was compared with the VEGFR-I selective and also heparin-binding form of placenta growth factor (PIGF-2) in vivo. Both heparin-binding homologues induced mobilization of endothelial progenitor cells from the bone marrow and gave rise to similar colony numbers of myeloic cells in a colony-forming assay. These findings suggest that both VEGFR-1 and VEGFR-2 are involved in stem cell mobilization.

AB - Vascular endothelial growth factor (VEGF-A) is the founding member of a family of angiogenic proteins with various binding abilities to three cognate VEGF receptors. Previously, a gene encoding from the genome of parapox orf virus (OV) with about 25% amino acid identity to mammalian VEGF-A was named VEGF-E and shown to bind and specifically activate the vascular endothelial growth factor receptor VEGFR-2 (KDR/flk-1). Here, we have generated a novel heparin-binding form of VEGF-E by introducing the heparin-domain of the human VEGF-Az65 splice variant into the viral VEGF-E protein. Recombinant heparin-binding VEGF-E (hbVEGF-E) is shown to stimulate proliferation and sprout formation of macro- and microvascular endothelial cells to a similar extent as the parental OV-VEGF-E but fails to activate peripheral mononuclear cells. However, hbVEGF-E is more potent in binding competition assays with primary human endothelial cells when compared to the OV-VEGF-E. This can be explained by our finding that binding of hbVEGF-E but not of parental OV-VEGF-E to the VEGFR-2 is strongly increased by the addition of neuropilin-1 (NP-1), a cognate co-receptor for VEGF-A. The engineered hbVEGF-E was compared with the VEGFR-I selective and also heparin-binding form of placenta growth factor (PIGF-2) in vivo. Both heparin-binding homologues induced mobilization of endothelial progenitor cells from the bone marrow and gave rise to similar colony numbers of myeloic cells in a colony-forming assay. These findings suggest that both VEGFR-1 and VEGFR-2 are involved in stem cell mobilization.

KW - Endothelial mitogens

KW - Heparin-binding growth factors

KW - KDR/vascular endothelial growth factor

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=1942535932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942535932&partnerID=8YFLogxK

U2 - 10.1023/B:AGEN.0000021391.88601.92

DO - 10.1023/B:AGEN.0000021391.88601.92

M3 - Article

C2 - 15041796

AN - SCOPUS:1942535932

VL - 6

SP - 201

EP - 211

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 3

ER -